Platform Licensing Sutro's site-specific and novel-format ADC platform (XpressCF) and the ongoing exatecan and dual-payload ADC programs create multiple licensing or co-development opportunities for pharma and biotech partners seeking accelerated ADC innovation.

Regulatory Collaboration The FDA collaboration to develop reference materials and improve regulatory standards signals demand for advanced analytical services, assay development and validation, reference material supply, and regulatory strategy support from a dedicated partner.

Manufacturing Partnerships With a robust but early-stage ADC pipeline, Sutro may seek scalable GMP manufacturing, process development, and tech transfer support, presenting opportunities for contract manufacturing and fill-finish partnerships.

Growth Capital Upcoming financing activity and leadership changes suggest a growth push, opening avenues for investment banking, financing advisory, equity underwriting, and strategic funding partnerships to accelerate pipeline expansion.

Pipeline Partnerships Active industry engagement and a progressing ADC pipeline create opportunities for collaboration deals around exatecan and dual-payload ADCs, as well as data-sharing and joint development with oncology-focused firms.